Our long-standing interest in the El-Deiry Lab has been on unraveling the cell death pathways induced by the p53 tumor suppressor and the TRAIL innate immune system, mechanisms of drug resistance including under hypoxia, and on developing novel therapeutics for cancer. Our group uses a range of techniques from cell biology, molecular biology, omics, co-culture and in vivo models, transgenic and patient-derived organoids, and clinical samples in our basic and translational research. We collaborate with other labs at Brown, Lifespan and industry and are using innovative research technologies, and clinical datasets to study the impact of therapeutics on the tumor microenvironment and drug resistance in various cancer types.